Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

579 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Author Correction: Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1.
Makino Y, Kamiyama Y, Brown JB, Tanaka T, Murakami R, Teramoto Y, Goto T, Akamatsu S, Terada N, Inoue T, Kodama T, Ogawa O, Kobayashi T. Makino Y, et al. Among authors: kamiyama y. Commun Biol. 2022 Jul 19;5(1):718. doi: 10.1038/s42003-022-03707-z. Commun Biol. 2022. PMID: 35854103 Free PMC article. No abstract available.
Downregulation of RalGTPase-activating protein promotes invasion of prostatic epithelial cells and progression from intraepithelial neoplasia to cancer during prostate carcinogenesis.
Uegaki M, Kita Y, Shirakawa R, Teramoto Y, Kamiyama Y, Saito R, Yoshikawa T, Sakamoto H, Goto T, Akamatsu S, Yamasaki T, Inoue T, Suzuki A, Horiuchi H, Ogawa O, Kobayashi T. Uegaki M, et al. Among authors: kamiyama y. Carcinogenesis. 2019 Dec 31;40(12):1535-1544. doi: 10.1093/carcin/bgz082. Carcinogenesis. 2019. PMID: 31058283
Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer.
Mizuno K, Sumiyoshi T, Okegawa T, Terada N, Ishitoya S, Miyazaki Y, Kojima T, Katayama H, Fujimoto N, Hatakeyama S, Shiota M, Yoshimura K, Matsui Y, Narita S, Matsumoto H, Kurahashi R, Kanno H, Ito K, Kimura H, Kamiyama Y, Sunada T, Goto T, Kobayashi T, Yamada H, Tsuchiya N, Kamba T, Matsuyama H, Habuchi T, Eto M, Ohyama C, Ito A, Nishiyama H, Okuno H, Kamoto T, Fujimoto A, Ogawa O, Akamatsu S. Mizuno K, et al. Among authors: kamiyama y. Clin Cancer Res. 2021 Nov 15;27(22):6164-6173. doi: 10.1158/1078-0432.CCR-21-2328. Epub 2021 Sep 15. Clin Cancer Res. 2021. PMID: 34526361
Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1.
Makino Y, Kamiyama Y, Brown JB, Tanaka T, Murakami R, Teramoto Y, Goto T, Akamatsu S, Terada N, Inoue T, Kodama T, Ogawa O, Kobayashi T. Makino Y, et al. Among authors: kamiyama y. Commun Biol. 2022 Apr 1;5(1):299. doi: 10.1038/s42003-022-03227-w. Commun Biol. 2022. PMID: 35365763 Free PMC article.
Identification of the α2 chain of interleukin-13 receptor as a potential biomarker for predicting castration resistance of prostate cancer using patient-derived xenograft models.
Nagai T, Terada N, Fujii M, Nagata Y, Nakahara K, Mukai S, Okasho K, Kamiyama Y, Akamatsu S, Kobayashi T, Iida K, Denawa M, Hagiwara M, Inoue T, Ogawa O, Kamoto T. Nagai T, et al. Among authors: kamiyama y. Cancer Rep (Hoboken). 2023 Feb;6(2):e1701. doi: 10.1002/cnr2.1701. Epub 2022 Aug 9. Cancer Rep (Hoboken). 2023. PMID: 36806727 Free PMC article.
[A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin].
Utsunomiya N, Matsumoto K, Tsunemori H, Muguruma K, Kawakita M, Kamiyama Y, Kanamaru S, Ito N, Tsukazaki H, Shirahase T, Takahashi T. Utsunomiya N, et al. Among authors: kamiyama y. Hinyokika Kiyo. 2016 Jul;62(7):341-7. doi: 10.14989/ActaUrolJap_62_7_341. Hinyokika Kiyo. 2016. PMID: 27569351 Free article. Clinical Trial. Japanese.
579 results